[ON THE SIGNIFICANCE OF THE GAMMA-GLUTAMYL TRANSPEPTIDASE ISOENZYMES IN CLINICAL DIAGNOSIS].

F. Kokot,J. Kuska

Abstract:

What problem does this paper attempt to address?

Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer

Philip Sutera,Yang Song,Amol C Shetty,Keara English,Kim Van der Eecken,Ozan Cem Guler,Jarey Wang,Yufeng Cao,Soha Bazyar,Sofie Verbeke,Jo Van Dorpe,Valérie Fonteyne,Bram De Laere,Mark Mishra,Zaker Rana,Jason Molitoris,Matthew Ferris,Ana Kiess,Daniel Y Song,Theodore DeWeese,Kenneth J Pienta,Christopher Barbieri,Luigi Marchionni,Lei Ren,Amit Sawant,Nicole Simone,Alejandro Berlin,Cem Onal,Phuoc T Tran,Piet Ost,Matthew P Deek

DOI: https://doi.org/10.1016/j.euo.2024.05.011

2024-06-10

Abstract:Background and objective: Oligometastatic castration-sensitive prostate cancer (omCSPC) represents an early state in the progression of metastatic disease for which patients experience better outcomes in comparison to those with higher disease burden. Despite the generally more indolent nature, there is still much heterogeneity, with some patients experiencing a more aggressive clinical course unexplained by clinical features alone. Our aim was to investigate correlation of tumor genomics with the mode of progression (MOP) and pattern of failure (POF) following first treatment (metastasis-directed and/or systemic therapy) for omCSPC. Methods: We performed an international multi-institutional retrospective study of men treated for metachronous omCSPC who underwent tumor next-generation sequencing with at least 1 yr of follow-up after their first treatment. Descriptive MOP and POF results are reported with respect to the presence of genomic alterations in pathways of interest. MOP was defined as class I, long-term control (LTC; no radiographic progression at last follow-up), class II, oligoprogression (1-3 lesions), or class III, polyprogression (≥4 lesions). POF included the location of lesions at first failure. Genomic pathways of interest included TP53, ATM, RB1, BRCA1/2, SPOP, and WNT (APC, CTNNB1, RNF43). Genomic associations with MOP/POF were compared using χ2 tests. Exploratory analyses revealed that the COSMIC mutational signature and differential gene expression were also correlated with MOP/POF. Overall survival (OS) was calculated via the Kaplan-Meier method from the time of first failure. Key findings and clinical implications: We included 267 patients in our analysis; the majority had either one (47%) or two (30%) metastatic lesions at oligometastasis. The 3-yr OS rate was significantly associated with MOP (71% for polyprogression vs 91% for oligoprogression; p = 0.005). TP53 mutation was associated with a significantly lower LTC rate (27.6% vs 42.3%; p = 0.04) and RB1 mutation was associated with a high rate of polyprogression (50% vs 19.9%; p = 0.022). Regarding POF, bone failure was significantly more common with tumors harboring TP53 mutations (44.8% vs25.9%; p = 0.005) and less common with SPOP mutations (7.1% vs 31.4%; p = 0.007). Visceral failure was more common with tumors harboring either WNT pathway mutations (17.2% vs 6.8%, p = 0.05) or SPOP mutations (17.9% vs 6.3%; p = 0.04). Finally, visceral and bone failures were associated with distinct gene-expression profiles. Conclusions and clinical implications: Tumor genomics provides novel insight into MOP and POF following treatment for metachronous omCSPC. Patients with TP53 and RB1 mutations have a higher likelihood of progression, and TP53, SPOP, and WNT pathway mutations may have a role in metastatic organotropism. Patient summary: We evaluated cancer progression after a first treatment for metastatic prostate cancer with up to five metastases. We found that mutations in certain genes were associated with the location and extent of further metastasis in these patients.
Clinical effectiveness of transfusion of granulocytes obtained by filtration or intermittent flow centrifugation

E. Morse,A. Katz,D. Buchholz,J. Houx

DOI: https://doi.org/10.1002/1097-0142(19810301)47:5<974::AID-CNCR2820470525>3.0.CO;2-X

IF: 6.9209

1981-03-01

Cancer

Abstract:Clinical effectiveness of granulocyte transfusions collected by filtration or by intermittent flow centrifugation was compared in this study. In 251 patients receiving at least four daily transfusions of these products, there was no difference in response rate (67% in each group) as determined by defervescence. The most important factor in the recovery of patients appeared to be the underlying disease causing the agranulocytosis. Patients whose marrows were temporarily suppressed by chemotherapy showed the highest recovery rates (82% lymphoma and carcinoma), whereas those with intrinsic disease in the marrow showed the lowest recovery rates (47% aplastic anemia, 63% acute leukemia). Cancer 47:974–977, 1981.
Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer

Philip Sutera,Yang Song,Kim Van der Eecken,Amol C Shetty,Keara English,Theresa Hodges,Jinhee Chang,Valérie Fonteyne,Zaker Rana,Lei Ren,Adrianna A Mendes,Nicolaas Lumen,Louke Delrue,Sofie Verbeke,Kathia De Man,Daniel Y Song,Kenneth Pienta,Felix Y Feng,Steven Joniau,Tamara Lotan,Barton Lane,Ana Kiess,Steven Rowe,Martin Pomper,Theodore DeWeese,Matthew Deek,Christopher Sweeney,Piet Ost,Phuoc T Tran

DOI: https://doi.org/10.1016/j.eururo.2023.04.025

Abstract:In metastatic castration-sensitive prostate cancer (mCSPC), disease volume plays an integral role in guiding treatment recommendations, including selection of docetaxel therapy, metastasis-directed therapy, and radiation to the prostate. Although there are multiple definitions of disease volume, they have commonly been studied in the context of metastases detected via conventional imaging (CIM). One such numeric definition of disease volume, termed oligometastasis, is heavily dependent on the sensitivity of the imaging modality. We performed an international multi-institutional retrospective review of men with metachronous oligometastatic CSPC (omCSPC), detected via either advanced molecular imaging alone (AMIM) or CIM. Patients were compared with respect to clinical and genomic features using the Mann-Whitney U test, Pearson's χ2 test, and Kaplan-Meier overall survival (OS) analyses with a log-rank test. A total of 295 patients were included for analysis. Patients with CIM-omCSPC had significantly higher Gleason grade group (p = 0.032), higher prostate-specific antigen at omCSPC diagnosis (8.0 vs 1.7 ng/ml; p < 0.001), more frequent pathogenic TP53 mutations (28% vs 17%; p = 0.030), and worse 10-yr OS (85% vs 100%; p < 0.001). This is the first report of clinical and biological differences between AMIM-detected and CIM-detected omCSPC. Our findings are particularly important for ongoing and planned clinical trials in omCSPC. PATIENT SUMMARY: Metastatic prostate cancer with just a few metastases only detected via newer scanning methods (called molecular imaging) is associated with fewer high-risk DNA mutations and better survival in comparison to metastatic cancer detected via conventional scan methods.
Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics

Philip Sutera,Kim Van Der Eecken,Amar U. Kishan,Anis Hamid,Emily Grist,Gerhardt Attard,Tamara Lotan,Adrianna A. Mendes,Channing J. Paller,Michael A. Carducci,Ashley Ross,Hao Wang,Ken Pienta,Felix Y. Feng,Emmanuel S. Antonarakis,Piet Ost,Daniel Y. Song,Stephen Greco,Curtiland Deville,Theodore DeWeese,Phuoc T. Tran,Matthew P. Deek

DOI: https://doi.org/10.1038/s41391-021-00484-4

2022-01-11

Prostate Cancer and Prostatic Diseases

Abstract:BackgroundSeveral definitions have attempted to stratify metastatic castrate-sensitive prostate cancer (mCSPC) into low and high-volume states. However, at this time, comparison of these definitions is limited. Here we aim to compare definitions of metastatic volume in mCSPC with respect to clinical outcomes and mutational profiles.MethodsWe performed a retrospective review of patients with biochemically recurrent or mCSPC whose tumors underwent somatic targeted sequencing. 294 patients were included with median follow-up of 58.3 months. Patients were classified into low and high-volume disease per CHAARTED, STAMPEDE, and two numeric (≤3 and ≤5) definitions. Endpoints including radiographic progression-free survival (rPFS), time to development of castration resistance (tdCRPC), and overall survival (OS) were evaluated with Kaplan–Meier survival curves and log-rank test. The incidence of driver mutations between definitions were compared.ResultsMedian OS and tdCRPC were shorter for high-volume than low-volume disease for all four definitions. In the majority of patients (84.7%) metastatic volume classification did not change across all four definitions. High volume disease was significantly associated with worse OS for all four definitions (CHAARTED: HR 2.89; p < 0.01, STAMPEDE: HR 3.82; p < 0.01, numeric ≤3: HR 4.67; p < 0.01, numeric ≤5: HR 3.76; p < 0.01) however, were similar for high (p = 0.95) and low volume (p = 0.79) disease across all four definitions. Those with discordant classification tended to have more aggressive clinical behavior and mutational profiles. Patients with low-volume disease and TP53 mutation experienced a more aggressive course with rPFS more closely mirroring high-volume disease.ConclusionsThe spectrum of mCSPC was confirmed across four different metastatic definitions for clinical endpoints and genetics. All definitions were generally similar in classification of patients, outcomes, and genetic makeup. Given these findings, the simplicity of numerical definitions might be preferred, especially when integrating metastasis directed therapy. Incorporation of tumor genetics may allow further refinement of current metastatic definitions.

oncology,urology & nephrology
Transcriptomic heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.

Philip Sutera,Amol Shetty,Alexander K. Hakansson,Kim Van der Eecken,Yang Song,Yang Liu,Valerie Fonteyne,Sofie Verbeke,Daniel Y. Song,Ashley Ross,Felix Y Feng,Silke Gillessen,Gerhardt Attard,Nicholas D. James,Tamara L. Lotan,Elai Davicioni,Christopher Sweeney,Phuoc T. Tran,Matthew Pierre Deek,Piet Ost

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.e17083

IF: 45.3

2023-06-01

Journal of Clinical Oncology

Abstract:e17083 Background: Metastatic castration-sensitive prostate cancer (mCSPC) is commonly partitioned into high- and low-volume subgroups which have demonstrated differential biology, prognosis, and response to therapy. Timing of metastasis has similarly demonstrated differences in clinical outcomes, however less is known about any potential underlying biologic differences between these disease states. Herein we aim to compare transcriptomic differences between synchronous and metachronous mCSPC and identify any differential responses to therapy. Methods: We performed an international multi-institutional retrospective review of men with mCSPC who completed RNA expression profiling evaluation of their primary tumor. Patients were stratified according to disease timing (synchronous vs metachronous). The primary endpoint was to identify differences in transcriptomic profiles between disease time. Median genomic scores between groups were compared with Mann-Whitney U test. Secondary analyses included determining clinical and transcriptomic variables associated with overall survival (OS) from time of metastasis. Survival analysis was performed with the Kaplan-Meier Method and Multivariable Cox regression. Results: 252 patients were included with a median follow-up of 39.6 months. Patients with synchronous disease experienced worse 5-yr OS (39% vs 79%, p<0.01) and demonstrated lower median Androgen Receptor Activity (AR-A) (11.78 vs 12.64, p<0.01) and Hallmark Androgen Response (HAR) (3.15 vs 3.32; p<0.01). Multivariable cox-regression identified only high-volume disease (HR=4.97, 95%CI 2.71-9.10; p<0.01) and HAR score (HR=0.51, 95%CI 0.28-0.88; p=0.02 significantly associated with OS. Finally, patients with synchronous (HR=0.47, 95%CI 0.30-0.72; <0.01) but not metachronous (HR=1.37, 95%CI 0.50-3.92; p=0.56) disease were found to have better OS with Androgen Receptor (AR) + non-AR combination therapy as compared to monotherapy (p value for interaction = 0.05). Conclusions: We have demonstrated a potential biologic difference between metastatic timing of mCSPC. Specifically, for patients with low volume disease, those with metachronous low volume disease have a more hormone dependent transcriptional profile and exhibit a better prognosis than synchronous low volume disease. [Table: see text]

oncology
Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.

P.A. Sutera,A.C. Shetty,A. Hakansson,K. Van der Eecken,Y. Song,Y. Liu,J. Chang,V. Fonteyne,A.A. Mendes,N. Lumen,L. Delrue,S. Verbeke,K. De Man,Z. Rana,T. Hodges,A. Hamid,N. Roberts,D.Y. Song,K. Pienta,A.E. Ross,F. Feng,S. Joniau,D. Spratt,S. Gillessen,G. Attard,N.D. James,T. Lotan,E. Davicioni,C. Sweeney,P.T. Tran,M.P. Deek,P. Ost

DOI: https://doi.org/10.1016/j.annonc.2023.04.515

IF: 51.769

2023-05-01

Annals of Oncology

Abstract:BACKGROUND: Metastatic castration-sensitive prostate cancer (mCSPC) is commonly classified into high- and low-volume subgroups which have demonstrated differential biology, prognosis, and response to therapy. Timing of metastasis has similarly demonstrated differences in clinical outcomes; however, less is known about any underlying biologic differences between these disease states. Herein, we aim to compare transcriptomic differences between synchronous and metachronous mCSPC and identify any differential responses to therapy.PATIENTS AND METHODS: We performed an international multi-institutional retrospective review of men with mCSPC who completed RNA expression profiling evaluation of their primary tumor. Patients were stratified according to disease timing (synchronous versus metachronous). The primary endpoint was to identify differences in transcriptomic profiles between disease timing. The median transcriptomic scores between groups were compared with the Mann-Whitney U test. Secondary analyses included determining clinical and transcriptomic variables associated with overall survival (OS) from the time of metastasis. Survival analysis was carried out with the Kaplan-Meier method and multivariable Cox regression.RESULTS: A total of 252 patients were included with a median follow-up of 39.6 months. Patients with synchronous disease experienced worse 5-year OS (39% versus 79%; P < 0.01) and demonstrated lower median androgen receptor (AR) activity (11.78 versus 12.64; P < 0.01) and hallmark androgen response (HAR; 3.15 versus 3.32; P < 0.01). Multivariable Cox regression identified only high-volume disease [hazard ratio (HR) = 4.97, 95% confidence interval (CI) 2.71-9.10; P < 0.01] and HAR score (HR = 0.51, 95% CI 0.28-0.88; P = 0.02) significantly associated with OS. Finally, patients with synchronous (HR = 0.47, 95% CI 0.30-0.72; P < 0.01) but not metachronous (HR = 1.37, 95% CI 0.50-3.92; P = 0.56) disease were found to have better OS with AR and non-AR combination therapy as compared with monotherapy (P value for interaction = 0.05).CONCLUSIONS: We have demonstrated a potential biologic difference between metastatic timing of mCSPC. Specifically, for patients with low-volume disease, those with metachronous low-volume disease have a more hormone-dependent transcriptional profile and exhibit a better prognosis than synchronous low-volume disease.

oncology
Combinatorial materials research applied to the development of new surface coatings I: a multiwell plate screening method for the high-throughput assessment of bacterial biofilm retention on surfaces.

S. Stafslien,J. Bahr,J. M. Feser,J. Weisz,B. Chisholm,T. E. Ready,P. Boudjouk

DOI: https://doi.org/10.1021/CC050047M

2006-03-01

Journal of Combinatorial Chemistry

Abstract:Combinatorial, high-throughput capabilities have been established to aid in the rapid development of new and effective antifouling marine coatings for naval applications. A biological screening process involving marine bacteria was developed that allows for rapid and effective quantification of bacterial biofilm growth and retention on large numbers of coating surfaces in parallel. The screening process involves (1) multiwell plate modifications for coating deposition, (2) deposition of combinatorial coating libraries via an automated liquid dispensing robot, (3) coating thickness measurements of cured coatings, (4) preconditioning of coatings via immersion in deionized water, (5) bacterial incubation, (6) plate processing, and (7) data analysis for identification of promising candidates. The details of the method developed are described in this document.
Clinical impact of mutations in driver oncogenes and TP53/RB1 in advanced prostate cancer.

Liat Hammer,Ryan Rebernick,Matthew McFarlane,Thomas Westbrook,Munna Hazime,Tanya Hammoud,Pin-en Chiu,Owens Xavier,Yi-Mi Wu,Dan R. Robinson,Daniel Eidelberg Spratt,Ajjai Shivaram Alva,William C. Jackson,Zachery R Reichert,Joshi J. Alumkal,Arul Chinnaiyan,Marcin Cieslik,Robert Timothy Dess

DOI: https://doi.org/10.1200/jco.2023.41.6_suppl.263

IF: 45.3

2023-02-20

Journal of Clinical Oncology

Abstract:263 Background: Prostate cancer (PCa) is characterized by considerable genetic heterogeneity, and complex genomic features may influence prognosis and treatment response. We created a database of aggressive PCa that integrates comprehensive genomic sequencing with detailed clinical outcomes to better understand the optimal use of genomic sequencing. Methods: From 4/2005-7/2021, PCa cancer patients older than 18 years of age underwent tissue collection for tumoral RNA-sequencing and tumor/normal whole exome sequencing at our institution (HUM00046018, HUM00048105, HUM00067928, SU2C). Genomic and transcriptomic sequencing data was processed using Turnkey Precision Oncology. Genetic alterations, including ETS fusions, SPOP, FOXA1 class 1, and CDK12 mutations, as well as TP53 and RB1 mutations were analyzed. Clinical data was collected from 05/2021-01/2022, and clinical associations (metastasis free survival (MFS), time to castrate resistant prostate cancer (CRPC), and overall survival (OS)) were determined. Results: Data was available for 325 men. Median follow up from diagnosis was 106 months (IQR, 90-121), median age at diagnosis was 61 (IQR, 54-67), and most (91%) presented with PCa adenocarcinoma (n=292/325). At diagnosis, 51% (n=165) had localized, 5% (n=18) had clinical node positive, and 40% (n=128) had de-novo M1 disease. At time of tissue sampling, 87% (n=283) had metastatic disease, and 59% (n=192) were castrate resistant. Established PCa driver mutations included 140 ETS fusions (49%), 26 SPOP mutations (9%), 22 FOXA1 class 1 mutations (8%), and 15 (5%) CDK12 mutations. For men with localized disease at diagnosis (n=197/325), ETS fusion was associated with improved MFS (HR: 0.55; 95% CI: 0.37-0.81), time to CRPC (HR: 0.53; 0.35-0.80), and OS (HR: 0.56; 0.35-0.89). SPOP mutations were also associated with improved prognosis in this population (n=197/325): MFS (HR: 0.45; 0.24-0.84), time to CRPC (HR: 0.36; 0.18-0.73), and OS (HR: 0.46; 0.21-0.99). TP53 mutations were identified in 38% (n=122) of all patients and were associated with worse OS from the time of biopsy after adjusting for PCa castration state and disease spread at biopsy (HR: 2.2; 1.7-2.9, p<0.001). RB1 mutations were identified in 12% (n=40; 24/40 also TP53 mutants). OS from the time of biopsy was worse in the presence of dual TP53/RB1 mutants when compared to TP53 or RB1 mutants alone, independent of the disease state at time of biopsy (HR, 4.3; 95%CI: 2.7-7.0). Conclusions: In a cohort of aggressive PCa, oncogenic driver mutations were associated with significant differences in prognosis. ETS fusions and SPOP mutations correlated with improved outcomes for men with localized disease at presentation. TP53 loss was associated with worse prognosis, as was the combination with RB1 loss, across the disease spectrum. Future efforts will focus on correlating sensitivity to PCa treatments with genetic alterations throughout the disease course.

oncology
Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients

Moom R Roosan,Isa Mambetsariev,Rebecca Pharaon,Jeremy Fricke,Angel R Baroz,Joseph Chao,Chen Chen,Mohd W Nasser,Ramakanth Chirravuri-Venkata,Maneesh Jain,Lynette Smith,Susan E Yost,Karen L Reckamp,Raju Pillai,Leonidas Arvanitis,Michelle Afkhami,Edward W Wang,Vincent Chung,Mihaela Cristea,Marwan Fakih,Marianna Koczywas,Erminia Massarelli,Joanne Mortimer,Yuan Yuan,Surinder K Batra,Sumanta Pal,Ravi Salgia

DOI: https://doi.org/10.3390/cancers13112776

2021-06-03

Abstract:Metastasis continues to be the primary cause of all cancer-related deaths despite the recent advancements in cancer treatments. To evaluate the role of mutations in overall survival (OS) and treatment outcomes, we analyzed 957 metastatic patients with seven major cancer types who had available molecular testing results with a FoundationOne CDx® panel. The most prevalent genes with somatic mutations were TP53, KRAS, APC, and LRP1B. In this analysis, these genes had mutation frequencies higher than in publicly available datasets. We identified that the somatic mutations were seven mutually exclusive gene pairs and an additional fifty-two co-occurring gene pairs. Mutations in the mutually exclusive gene pair APC and CDKN2A showed an opposite effect on the overall survival. However, patients with CDKN2A mutations showed significantly shorter OS (HR: 1.72, 95% CI: 1.34-2.21, p < 0.001) after adjusting for cancer type, age at diagnosis, and sex. Five-year post metastatic diagnosis survival analysis showed a significant improvement in OS (median survival 28 and 43 months in pre-2015 and post-2015 metastatic diagnosis, respectively, p = 0.00021) based on the year of metastatic diagnosis. Although the use of targeted therapies after metastatic diagnosis prolonged OS, the benefit was not statistically significant. However, longer five-year progression-free survival (PFS) was significantly associated with targeted therapy use (median 10.9 months (CI: 9.7-11.9 months) compared to 9.1 months (CI: 8.1-10.1 months) for non-targeted therapy, respectively, p = 0.0029). Our results provide a clinically relevant overview of the complex molecular landscape and survival mechanisms in metastatic solid cancers.
Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer

Matthew P Deek,Philip Sutera,Yuezhou Jing,Robert Gao,Emily Rothman,Heather Day,David Chang,Piet Dirix,Andrew J Armstrong,Bethany Campbell,Fernando Lopez Campos,Miguel Berenguer,Matthew Ramotar,Antonio Conde-Moreno,Alejandro Berlin,Davide Giovanni Bosetti,Niall Corcoran,Bridget Koontz,Carole Mercier,Shankar Siva,David Pryor,Piet Ost,Mai Anh Huynh,Stephanie Kroeze,Bradley Stish,Ana Kiess,Bruce Trock,Phuoc T Tran,Silke Gillessen,Christopher Sweeney

DOI: https://doi.org/10.1016/j.euo.2024.03.010

2024-04-02

Abstract:Background: Metastasis-directed therapy (MDT) is increasingly being used in oligometastatic castration-sensitive prostate cancer (omCSPC). However, it is currently unclear how to optimally integrate MDT with the standard of care of systemic hormonal therapy. Objective: To report long-term outcomes of MDT alone versus MDT and a defined course of androgen deprivation therapy (ADT) in omCSPC. Design, setting, and participants: Here, a multicenter, international retrospective cohort of omCSPC as defined by conventional imaging was reported. Outcome measurements and statistical analysis: Biochemical progression-free survival (bPFS), distant progression-free survival (dPFS), and combined biochemical or distant progression-free survival (cPFS) were evaluated with Kaplan-Meier and multivariable Cox proportional hazard regression models. Results and limitations: A total of 263 patients were included, 105 with MDT + ADT and 158 with MDT alone. The majority of patients had metachronous disease (90.5%). Five-year bPFS, dPFS, and cPFS were, respectively, 24%, 41%, and 19% in patients treated with MDT + ADT and 11% (hazard ratio [HR] 0.48, 95% confidence interval [CI] 0.36-0.64), 29% (HR 0.56, 95% CI 0.40-0.78), and 9% (HR 0.50, 95% CI 0.38-0.67) in patients treated with MDT alone. On a multivariable analysis adjusting for pretreatment variables, the use of ADT was associated with improved bPFS (HR 0.43, p < 0.001), dPFS (HR 0.45, p = 0.002), and cPFS (HR 0.44, p < 0.001). Conclusions: In this large multi-institutional report, the addition of concurrent ADT to MDT appears to improve time to prostate-specific antigen progression and distant recurrence, noting that about 10% patients had durable control with MDT alone. Ongoing phase 3 studies will help further define treatment options for omCSPC. Patient summary: Here, we report a large retrospective review evaluating the outcomes of metastasis-directed therapy with or without a limited course of androgen deprivation for patients with oligometastatic castration-sensitive prostate cancer. This international multi-institutional review demonstrates that the addition of androgen deprivation therapy to metastasis-directed therapy (MDT) improves progression-free survival. While a proportion of patients appear to have long-term disease control with MDT alone, further work in biomarker discovery is required to better identify which patients would be appropriate for de-escalated therapy.
Oligometastatic Prostate Cancer: Current Status and Future Challenges

Jadvar,H.,Abreu,A. L.,Ballas,L. K.,Quinn,D. I.

DOI: https://doi.org/10.2967/jnumed.121.263124

2022-11-02

Journal of Nuclear Medicine

Abstract:In accordance with the spectrum theory of metastatic disease, an oligometastatic clinical state has been proposed as an intermediary step along the natural history of cancer with few (typically 1–3) metastatic lesions identifiable on imaging that may be amenable to metastasis-directed therapy. Effective therapy of oligometastatic disease is anticipated to impact cancer evolution by delaying progression and improving patient outcome at a minimal or acceptable cost of toxicity. There has been increasing recognition of oligometastatic disease in prostate cancer with the advent of new-generation imaging agents, most notably the recently approved PET radiotracers based on targeting prostate-specific membrane antigen. Early clinical trials with metastasis-directed therapy of oligometastases have provided evidence for delaying the employment of systematic therapy and improving outcome in selected patients. Despite these encouraging results, much needs to be investigated and learned about the underlying biology of the oligometastatic state along the evolutionary clinical course of prostate cancer, the identification of relevant imaging and nonimaging predictive and prognostic biomarkers, and the development of treatment strategies to optimize short-term and long-term patient outcome. We provide a review of the current status and the lingering challenges of this rapidly evolving clinical space in prostate cancer.

radiology, nuclear medicine & medical imaging
PIK3/Akt/mTOR pathway alterations in metastatic castration‐sensitive prostate cancer

Philip Sutera,Jongmyung Kim,Ritesh Kumar,Rebecca A. Deek,Ryan Stephenson,Tina Mayer,Biren Saraiya,Saum Ghodoussipour,Thomas Jang,David Golombos,Vignesh Packiam,Ronald Ennis,Lara Hathout,Salma K. Jabbour,Ozan Guler,Cem Onal,Phuoc T. Tran,Matthew P. Deek

DOI: https://doi.org/10.1002/pros.24765

2024-07-19

The Prostate

Abstract:Background Alterations in the PIK3/Akt/mTOR pathway are commonly seen in metastatic castration‐sensitive prostate cancer (mCSPC), however their role in outcomes is unknown. We aim to evaluate the prognostic significance as well as the genetic landscape of PIK3/Akt/mTOR pathway alteration in mCSPC. Methods Fourhundred and seventy‐two patients with mCSPC were included who underwent next generation sequencing. PIK3/Akt/mTor pathway alterations were defined as mutations in Akt1, mTOR, PIK3CA, PIK3CB, PIK3R1, PTEN, TSC1, and TSC2. Endpoints of interests were radiographic progression‐free survival (rPFS), time to development of castration resistant prostate cancer (tdCRPC), and overall survival (OS). Kaplan–Meier analysis was performed and Cox regression hazard ratios (HR) were calculated. Results One hundred and fifty‐two (31.9%) patients harbored a PIK3/Akt/mTOR pathway alteration. Median rPFS and tdCRPC were 23.7 and 21.0 months in PIK3/Akt/mTOR altered compared to 32.8 (p = 0.08) and 32.1 months (p = 0.002) in wildtype tumors. On multivariable analysis PIK3/Akt/mTOR pathway alterations were associated with tdCRPC (HR 1.43, 95% CI, 1.05–1.94, p = 0.02), but not rPFS [Hazard ratio (HR) 1.20, 95% confidence interval (CI), 0.90–1.60, p = 0.21]. PIK3/Akt/mTOR pathway alterations were more likely to be associated with concurrent mutations in TP53 (40% vs. 28%, p = 0.01) and TMPRSS2‐ERG (37% vs. 26%, p = 0.02) than tumors without PIK3/Akt/mTOR pathway alterations. Concurrent mutations were typically associated with shorter median times to rPFS and tdCRPC. DAVID analysis showed p53 signaling and angiogenesis pathways were enriched in PIK3/Akt/mTOR pathway altered tumors while beta‐catenin binding and altered BRCA pathway were enriched in PIK3/Akt/mTOR pathway wildtype tumors. Conclusions PIK3/Akt/mTOR pathway alterations were common in mCSPC and associated with poorer prognosis. The genetic landscape of PIK3/Akt/mTOR pathway altered tumors differed from wildtype tumors. Additional studies are needed to better understand and target the PIK3/Akt/mTOR pathway in mCSPC.

endocrinology & metabolism,urology & nephrology
Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review

Kim Van der Eecken,Jan Vanwelkenhuyzen,Matthew P Deek,Phuoc T Tran,Evan Warner,Alexander W Wyatt,Edmond M Kwan,Sofie Verbeke,Jo Van Dorpe,Valérie Fonteyne,Nicolaas Lumen,Bram De Laere,Piet Ost

DOI: https://doi.org/10.1016/j.euo.2021.10.005

Abstract:Context: Multiple studies have reported on the genomic characteristics of metastatic hormone-sensitive prostate cancer (mHSPC). The impact of these findings on prognostication, treatment selection, and clinical trial design remains unclear. Objective: To summarise genomic alteration prevalences in liquid and/or tissue biopsies, infer their clinical implications, and compare genomic alteration frequencies across different disease states and clinical phenotypes. Evidence acquisition: The PubMed and Web of Knowledge databases were systematically searched up to January 2021. Quality assessment was performed using the Joanna Briggs Institute Critical Appraisal tools. Evidence synthesis: In total, 11 studies encompassing 1682 mHSPC patients were included. High-volume disease was associated with more frequent alterations in TP53, DNA damage repair, and Wnt pathways. Tumours from patients with de novo mHSPC were enriched for alterations in TP53 and CDK12 compared with recurrent disease. Alterations in AR, TP53, cell cycle signalling, and MYC were associated with a poorer clinical outcome. A comparative analysis of gene alteration frequencies across disease states revealed a relative increase from localised to castration-resistant tumours, with noteworthy enrichment of CTNNB1 alterations in mHSPC (5%), which warrants further investigation. This study was limited by variability in methodology and definitions used among the eligible studies, including differences in sequencing methods, analytes (being either tissue or liquid), alteration calling thresholds, and target patient populations with a relative under-representation of recurrent metastatic disease. Conclusions: Several genomic alterations are associated with differential prognosis and clinical phenotypes in mHSPC. We urge that emerging data on these potential predictive biomarkers must be validated in biomarker-driven randomised controlled trials before any clinical implementation. Alignment of the assay methodology and reporting will be critical for ensuring rapid scalability. Patient summary: We reviewed current data on genomic alterations of metastatic hormone-sensitive prostate cancer, and summarised key genomic subtypes that associate with specific clinical phenotypes and treatment outcomes.
Differences in genomic, transcriptomic, and immune landscape of prostate cancer (PCa) based on site of metastasis (mets).

Umang Swami,Shayan Nazari,Georges Gebrael,Andrew Elliott,Aditya Bagrodia,Dhruv Puri,Chadi Nabhan,Rana R. McKay,Emmanuel S. Antonarakis,Neeraj Agarwal

DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.21

IF: 45.3

2024-02-01

Journal of Clinical Oncology

Abstract:21 Background: In patients with metastatic PCa, specific sites of mets are associated with differential overall survival, with lymph node (LN) only disease having the best survival, followed by bone, lung, and liver, with each showing progressively worse survival. However, the biology of tropism to specific sites and differential outcomes has not been fully explored. Herein, utilizing a large, multi-institutional, real-world dataset, we hypothesized that differences in molecular and immune landscape of PCa based on site of mets may explain different clinical outcomes. Methods: DNA (592-gene panel or whole exome) and RNA (whole transcriptome) sequencing was performed for primary PCa (PPCa) and unpaired PCa mets sites (non-visceral: NV and visceral: V) and sequenced at Caris Life Sciences (Phoenix, AZ). Mismatch repair deficiency/microsatellite instability-high (dMMR/MSI-H) was tested by IHC/NGS, respectively. Tumor mutational burden (TMB) (high >10 mut/Mb) was assessed. Androgen receptor (AR) signaling score and Neuroendocrine Prostate Cancer (NEPC) score were calculated using previously defined RNA-based signatures. Pathway enrichment was determined by Gene Set Enrichment Analysis (GSEA). Immune cell fractions calculated by deconvolution of WTS using quanTIseq. Statistical significance was determined by chi-square and Mann-Whitney U tests. All analyses done with CODEai. Results: 6074 PCa samples, including 3411 PPCa, 1634 NV (bone = 784, LN = 850) and 1029 V (liver: 468, lung: 177, bladder: 241, other: 143) were evaluated. Age at sample collection ranged 30 to 70+ years. Compared to PPCa, significantly higher mutation rates were observed for multiple genes in V (RB1 8% vs 3%, TP53 43% vs 31%, PTEN 12 % vs 8%, CTNNB1 8% vs 3%, AR 13% vs 1%, APC 15% vs 5%, AKT1 4% vs 2%; p<0.05 for all) and NV mets (AR 9% vs 1%, SPOP 7% vs 10%, TP53 38% vs 31%, CTNNB1 6% vs 3%, and KMT2C 8 % vs 5%; p<0.05 for all). Alterations of RB1, APC and AR were more frequent, and SPOP less common in liver mets compared to PPCa, while SPOP, KRAS, PIK3CA, APC and BAP1 mutations were more common in lung mets (p < 0.05 for all). Compared to PPCa, V and NV mets had higher AR signaling and interferon-γ scores, while V mets had higher NEPC scores and were more frequently PD-L1+ (SP142) and TMB-high (p<0.05 for all). No differences in dMMR/MSI-H was observed between PPCa, V and NV mets. AR-V7 variant prevalence was significantly higher in V (36%) and NV (33%) mets compared to PPCa (7%, p-value < 0.05). GSEA identified E2F, G2M checkpoint and MYC target pathways as being more upregulated in both V and NV mets compared to PPCa (q<0.05). Compared to PPCa, V and NV mets were significantly less enriched in macrophage M2, NK cells and Tregs, while V mets were also less enriched in B cells and neutrophils (p<0.05). Conclusions: We elucidate molecular and immunologic mechanisms of metastatic tropism in advanced PCa. These data may facilitate future drug development.

oncology
Integrative Clinical Genomics of Advanced Prostate Cancer

Dan Robinson,Eliezer M. Van Allen,Yi-Mi Wu,Nikolaus Schultz,Robert J. Lonigro,Juan-Miguel Mosquera,Bruce Montgomery,Mary-Ellen Taplin,Colin C. Pritchard,Gerhardt Attard,Himisha Beltran,Wassim Abida,Robert K. Bradley,Jake Vinson,Xuhong Cao,Pankaj Vats,Lakshmi P. Kunju,Maha Hussain,Felix Y. Feng,Scott A. Tomlins,Kathleen A. Cooney,David C. Smith,Christine Brennan,Javed Siddiqui,Rohit Mehra,Yu Chen,Dana E. Rathkopf,Michael J. Morris,Stephen B. Solomon,Jeremy C. Durack,Victor E. Reuter,Anuradha Gopalan,Jianjiong Gao,Massimo Loda,Rosina T. Lis,Michaela Bowden,Stephen P. Balk,Glenn Gaviola,Carrie Sougnez,Manaswi Gupta,Evan Y. Yu,Elahe A. Mostaghel,Heather H. Cheng,Hyojeong Mulcahy,Lawrence D. True,Stephen R. Plymate,Heidi Dvinge,Roberta Ferraldeschi,Penny Flohr,Susana Miranda,Zafeiris Zafeiriou,Nina Tunariu,Joaquin Mateo,Raquel Perez-Lopez,Francesca Demichelis,Brian D. Robinson,Marc Schiffman,David M. Nanus,Scott T. Tagawa,Alexandros Sigaras,Kenneth W. Eng,Olivier Elemento,Andrea Sboner,Elisabeth I. Heath,Howard I. Scher,Kenneth J. Pienta,Philip Kantoff,Johann S. de Bono,Mark A. Rubin,Peter S. Nelson,Levi A. Garraway,Charles L. Sawyers,Arul M. Chinnaiyan,Eliezer M. Van Allen,Robert J. Lonigro,Colin C. Pritchard,Robert K. Bradley,Lakshmi P. Kunju,Felix Y. Feng,Scott A. Tomlins,Kathleen A. Cooney,David C. Smith,Dana E. Rathkopf,Michael J. Morris,Stephen B. Solomon,Jeremy C. Durack,Victor E. Reuter,Rosina T. Lis,Stephen P. Balk,Evan Y. Yu,Elahe A. Mostaghel,Heather H. Cheng,Lawrence D. True,Stephen R. Plymate,Brian D. Robinson,David M. Nanus,Scott T. Tagawa,Kenneth W. Eng,Elisabeth I. Heath,Howard I. Scher,Kenneth J. Pienta,Johann S. de Bono,Mark A. Rubin,Peter S. Nelson,Levi A. Garraway,Charles L. Sawyers,Arul M. Chinnaiyan

DOI: https://doi.org/10.1016/j.cell.2015.05.001

IF: 64.5

2015-05-01

Cell

Abstract:Toward development of a precision medicine framework for metastatic, castration-resistant prostate cancer (mCRPC), we established a multi-institutional clinical sequencing infrastructure to conduct prospective whole-exome and transcriptome sequencing of bone or soft tissue tumor biopsies from a cohort of 150 mCRPC affected individuals. Aberrations of AR, ETS genes, TP53, and PTEN were frequent (40%-60% of cases), with TP53 and AR alterations enriched in mCRPC compared to primary prostate cancer. We identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, β-catenin, and ZBTB16/PLZF. Moreover, aberrations of BRCA2, BRCA1, and ATM were observed at substantially higher frequencies (19.3% overall) compared to those in primary prostate cancers. 89% of affected individuals harbored a clinically actionable aberration, including 62.7% with aberrations in AR, 65% in other cancer-related genes, and 8% with actionable pathogenic germline alterations. This cohort study provides clinically actionable information that could impact treatment decisions for these affected individuals.

cell biology,biochemistry & molecular biology
The genomic and epigenomic landscape of double-negative metastatic prostate cancer

Arian Lundberg,Meng Zhang,Rahul Aggarwal,Haolong Li,Li Zhang,Adam Foye,Martin Sjöström,Jonathan Chou,Kevin Chang,Thaidy Moreno-Rodriguez,Raunak Shrestha,Avi Baskin,Xiaolin Zhu,Alana S. Weinstein,Noah Younger,Joshi J. Alumkal,Tomasz M. Beer,Kim N. Chi,Christopher P. Evans,Martin Gleave,Primo N. Lara,Rob E. Reiter,Matthew B. Rettig,Owen N. Witte,Alexander W. Wyatt,Felix Y. Feng,Eric J. Small,David A. Quigley

DOI: https://doi.org/10.1158/0008-5472.can-23-0593

IF: 11.2

2023-06-09

Cancer Research

Abstract:Systemic targeted therapy in prostate cancer is primarily focused on ablating androgen signaling. Androgen deprivation therapy and second-generation androgen receptor (AR)-targeted therapy selectively favor the development of treatment-resistant subtypes of metastatic castration-resistant prostate cancer (mCRPC), defined by AR and neuroendocrine (NE) markers. Molecular drivers of double-negative (AR-/NE-) mCRPC are poorly defined. In this study, we comprehensively characterized treatment-emergent mCRPC by integrating matched RNA sequencing, whole-genome sequencing, and whole-genome bisulfite sequencing from 210 tumors. AR-/NE- tumors were clinically and molecularly distinct from other mCRPC subtypes, with the shortest survival, amplification of the chromatin remodeler CHD7, and PTEN loss. Methylation changes in CHD7 candidate enhancers were linked to elevated CHD7 expression in AR-/NE+ tumors. Genome-wide methylation analysis nominated KLF5 as a driver of the AR-/NE- phenotype, and KLF5 activity was linked to RB1 loss. These observations reveal the aggressiveness of AR-/NE- mCRPC and could facilitate the identification of therapeutic targets in this highly aggressive disease.

oncology
Impact of TP53 , RB1 , and PTEN mutations on overall survival in metastatic prostate cancer: A multi-center study via the Guardian Research Network.

Mohammad Arfat Ganiyani,Pushan Prabhakar,Atulya Aman Khosla,Shreyas S Bellur,Arjun Pon Avudaiappan,Liz Bond,Suresh Marada,Andrea McCracken,Charlie Hurmiz,Bruno R. Bastos,Rohan Garje

DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.82

IF: 45.3

2024-02-01

Journal of Clinical Oncology

Abstract:82 Background: The treatment paradigm for metastatic prostate cancer has significantly improved in the past decade. Nevertheless, there remains an unmet need for novel biomarker-driven risk stratification. Studies have shown that genetic alterations in any of the PTEN, RB1, and TP53 genes influence the prognosis, potential for androgen independence and overall survival of individuals diagnosed with advanced prostate cancer. Based on these findings, we compared survival rates by contrasting patients with any of these mutations to those lacking them, using an extensive real-world sample from community oncology centers across the Guardian Research network (GRN). Methods: All patients diagnosed with metastatic prostate cancer who had undergone Next-Generation Sequencing (NGS) were included across an oncology-focused hospital consortium network database (GRN). Study participants were classified into two cohorts based on the presence or absence of biomarkers. Patients harboring at least one of the following genomic alterations— TP53, Rb, or PTEN—were categorized as "biomarker-positive." Those without these mutations were designated as "biomarker negative." Overall survival (OS) was compared between the two cohorts by Kaplan-Meier Curve analysis. Results: We identified 350 patients with metastatic prostate cancer, of which 140 were biomarker positive and 210 were biomarker negative. The biomarker-positive cohort had a lower overall survival (p=0.002) when compared to the biomarker-negative cohort. For the sub-group with a minimum follow up of four years, median survival was 35.8 months vs 67.2 months for biomarker marker positive and negative cohorts, respectively. Furthermore, the biomarker-positive cohort was associated with significantly higher number of patients with bone and liver metastases. Conclusions: Our study indicates poor overall survival in patients with TP53, RB1, and PTEN mutated prostate cancer, underscoring the need for novel treatment strategies for this aggressive disease genotype. Future studies based on genomic risk stratification are needed to customize therapies through appropriate intensification or de-intensification based on individual genomic profiles. [Table: see text]

oncology
Mobilization of chondroitin sulphate by nitrilotriacetic acid.

L. Jaques,T. K. Sue

DOI: https://doi.org/10.1016/0041-008X(75)90147-7

IF: 4.46

1975-12-01

Toxicology and Applied Pharmacology

Abstract:
Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients

Surendra Dasari,Michael R. McCarthy,Antonina A. Wojcik,Beth A. Pitel,Arpan Samaddar,Burak Tekin,Rumeal D. Whaley,Aditya Raghunathan,Loren Herrera Hernandez,Rafael E. Jimenez,Brad J. Stish,R. Houston Thompson,Bradley C. Leibovich,Stephen A. Boorjian,R. Jeffrey Karnes,Daniel S. Childs,J. Fernando Quevedo,Eugene D. Kwon,Lance C. Pagliaro,Brian A. Costello,Kevin C. Halling,John C. Cheville,Benjamin R. Kipp,Sounak Gupta

DOI: https://doi.org/10.1038/s41391-024-00814-2

2024-02-28

Prostate Cancer and Prostatic Diseases

Abstract:Primary prostatic adenocarcinoma (pPC) undergoes genomic evolution secondary to therapy-related selection pressures as it transitions to metastatic noncastrate (mNC-PC) and castrate resistant (mCR-PC) disease. Next generation sequencing results were evaluated for pPC ( n = 97), locally advanced disease (involving urinary bladder/rectum, n = 12), mNC-PC ( n = 21), and mCR-PC ( n = 54). We identified enrichment of TP53 alterations in high-grade pPC, TP53/RB1 alterations in HGNE disease, and AR alterations in metastatic and castrate resistant disease. Actionable alterations (MSI-H phenotype and HRR genes) were identified in approximately a fifth of all cases. These results help elucidate the landscape of genomic alterations across the clinical spectrum of prostate cancer.

oncology,urology & nephrology
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer

Mark P Labrecque,Ilsa M Coleman,Lisha G Brown,Lawrence D True,Lori Kollath,Bryce Lakely,Holly M Nguyen,Yu C Yang,Rui M Gil da Costa,Arja Kaipainen,Roger Coleman,Celestia S Higano,Evan Y Yu,Heather H Cheng,Elahe A Mostaghel,Bruce Montgomery,Michael T Schweizer,Andrew C Hsieh,Daniel W Lin,Eva Corey,Peter S Nelson,Colm Morrissey,Mark P. Labrecque,Ilsa M. Coleman,Lisha G. Brown,Lawrence D. True,Holly M. Nguyen,Yu C. Yang,Rui M. Gil da Costa,Celestia S. Higano,Evan Y. Yu,Heather H. Cheng,Elahe A. Mostaghel,Michael T. Schweizer,Andrew C. Hsieh,Daniel W. Lin,Peter S. Nelson

DOI: https://doi.org/10.1172/jci128212

IF: 19.456

2019-09-16

Journal of Clinical Investigation

Abstract:Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with diverse drivers of disease progression and mechanisms of therapeutic resistance. We conducted deep phenotypic characterization of CRPC metastases and patient-derived xenograft (PDX) lines using whole-genome RNA sequencing, gene set enrichment analysis, and immunohistochemistry. Our analyses revealed 5 mCRPC phenotypes based on the expression of well-characterized androgen receptor (AR) or neuroendocrine (NE) genes: AR-high tumors (ARPC), AR-low tumors (ARLPC), amphicrine tumors composed of cells coexpressing AR and NE genes (AMPC), double-negative tumors (i.e., AR<sup>–</sup>/NE<sup>–</sup>; DNPC), and tumors with small cell or NE gene expression without AR activity (SCNPC). RE1 silencing transcription factor (REST) activity, which suppresses NE gene expression, was lost in AMPC and SCNPC PDX models. However, knockdown of REST in cell lines revealed that attenuated REST activity drives the AMPC phenotype but is not sufficient for SCNPC conversion. We also identified a subtype of DNPC tumors with squamous differentiation and generated an encompassing 26-gene transcriptional signature that distinguished the 5 mCRPC phenotypes. Together, our data highlight the central role of AR and REST in classifying treatment-resistant mCRPC phenotypes. These molecular classifications could potentially guide future therapeutic studies and clinical trial design.

medicine, research & experimental

[ON THE SIGNIFICANCE OF THE GAMMA-GLUTAMYL TRANSPEPTIDASE ISOENZYMES IN CLINICAL DIAGNOSIS].

Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer

Clinical effectiveness of transfusion of granulocytes obtained by filtration or intermittent flow centrifugation

Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer

Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics

Transcriptomic heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.

Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.

Combinatorial materials research applied to the development of new surface coatings I: a multiwell plate screening method for the high-throughput assessment of bacterial biofilm retention on surfaces.

Clinical impact of mutations in driver oncogenes and TP53/RB1 in advanced prostate cancer.

Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients

Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer

Oligometastatic Prostate Cancer: Current Status and Future Challenges

PIK3/Akt/mTOR pathway alterations in metastatic castration‐sensitive prostate cancer

Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review

Differences in genomic, transcriptomic, and immune landscape of prostate cancer (PCa) based on site of metastasis (mets).

Integrative Clinical Genomics of Advanced Prostate Cancer

The genomic and epigenomic landscape of double-negative metastatic prostate cancer

Impact of TP53 , RB1 , and PTEN mutations on overall survival in metastatic prostate cancer: A multi-center study via the Guardian Research Network.

Mobilization of chondroitin sulphate by nitrilotriacetic acid.

Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients

Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer